Abstract 190P
Background
Perioperative chemotherapy(CT) for resectable locally advanced gastric or gastroesophageal junction(G/GEJ) adenocarcinoma has favourable outcomes. Immune checkpoint inhibitors(ICIs) combined with CT have some efficacy in advanced G/GEJ adenocarcinoma. However, the application of ICIs in resectable locally advanced G/GEJ adenocarcinoma remains to be explored. Here, this clinical trial evaluates efficacy and safety of perioperative ICI(Camrelizumab) +CT(XELOX) in resectable locally advanced G/GEJ adenocarcinoma.
Methods
Treatment-naive patients(pts) with cT3-4aN1-3M0 resectable locally advanced G/GEJ adenocarcinoma were recruited to receive Camrelizumab(200mg, iv) on D1, Oxaliplatin(130 mg/m2, iv) on D1 and Capecitabine(1000 mg/m2, po, bid) on D1∼14 Q3W for 4 cycles, followed by surgery and adjuvant Camrelizumab+CT Q3W for 4 cycles. The primary endpoint was pCR rate. The secondary endpoints were MPR rate, ORR, EFS, DFS, safety and feasibility of surgery. The exploratory endpoint was correlation between PD-L1 and TMB expression and efficacy.
Results
From 9/2020 to 1/2023, 46 pts were enrolled, received and completed neoadjuvant treatment, 43 of which had underwent D2 resection. 38 pts received, but 35 pts completed adjuvant treatment. In the ITT analysis set, pCR(TRG1a) occurred in 9 pts(19.6%, 95%CI: 9.9%-34.4%), and MPR(TRG1a/b) occurred in 25 pts(54.3%, 95%CI: 39.2%-68.8%). TRG1b, TRG2 and TRG3 were observed in 16(34.8%), 12 (26.1%) and 6(13.0%) pts, respectively. ORR was 69.6%(95%CI: 54.1%-81.2%), of which 12 pts achieved CR and 20 pts achieved PR. 1-year EFS and DFS achieved 93.101% and 93.108% respectively. Treatment-related adverse events(TRAE) occurred in 91.3% pts, and grade 3 TRAE occurred in 19.6% pts. No grade 4–5 TRAEs were observed. The toxicity and post-surgery complications were limited. Surgical feasibility was not affected.
Conclusions
Among patients with resectable locally advanced G/GEJ adenocarcinoma, neoadjuvant Camrelizumab combined with CT followed by surgery and adjuvant treatment demonstrated good efficacy and safety, providing a new treatment option for locally advanced G/GEJ adenocarcinoma.
Clinical trial identification
NCT05715632.
Editorial acknowledgement
Legal entity responsible for the study
the authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
194P - Real-world outcomes of cadonilimab (PD-1/CTLA-4 bispecific antibody) plus chemotherapy as first-line treatment in advanced gastric (G) or gastroesophageal junction (GEJ) cancer with PD-L1 CPS≤5
Presenter: Qi Xu
Session: Poster Display
Resources:
Abstract
195P - Ferroptosis signatures in pancreatic ductal adenocarcinomas and their role in patient survival: A translational unsupervised clustering analysis
Presenter: Quoc-Huy Trinh
Session: Poster Display
Resources:
Abstract
196P - Clinical significance of circulating CD8+ and CD4+ T cell proliferation in advanced gastric cancer receiving first-line chemotherapy
Presenter: In-Ho Kim
Session: Poster Display
Resources:
Abstract
197P - Treatment patterns and clinical outcomes of patients with unresectable advanced or metastatic (UAM) gastric/gastroesophageal junction adenocarcinoma (GA/GEJA) in China: A multicenter real-world study
Presenter: Yanqiao Zhang
Session: Poster Display
Resources:
Abstract
198P - Effectiveness of lenvatinib in patients with unresectable hepatocellular carcinoma: A multicenter observational study in Japan
Presenter: Namiki Izumi
Session: Poster Display
Resources:
Abstract
199P - Efficacy of endostar in combination with concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of esophagus: A randomized, open-label, phase II trial
Presenter: Yuexiao Qi
Session: Poster Display
Resources:
Abstract
200P - Prognosis of patients with hepatocellular carcinoma treated with transarterial chemoembolization: Development and validation of the ALFP score
Presenter: Baocuo Gong
Session: Poster Display
Resources:
Abstract
201P - A phase II study of serplulimab (a programmed death-1 inhibitor) with or without HLX04 (a bevacizumab biosimilar) for the treatment of advanced hepatocellular carcinoma
Presenter: Zhenggang Ren
Session: Poster Display
Resources:
Abstract
202P - Comparison of liver injury after transcatheter arterial chemoembolization and hepatic arterial infusion chemotherapy for intermediate and advanced hepatocellular carcinoma
Presenter: Yongru Chen
Session: Poster Display
Resources:
Abstract
203P - Neoadjuvant durvalumab plus chemotherapy for resectable locally advanced esophageal squamous cell carcinoma (ESCC)
Presenter: Jia He
Session: Poster Display
Resources:
Abstract